Biogen’s strategic turn to New Ventures

With its new corporate VC arm, Biogen aims to advance an array of technologies and therapeutic modalities in disease areas that could eventually feed assets into its own pipeline, but with far greater capital efficiency than building the capabilities in-house.

Launched last month, Biogen New Ventures is overseen by Adam Feire, head of business development and external innovation at Biogen Inc. (NASDAQ:BIIB), and former Atlas Venture principal Chelsea Johnson, who is head of New Ventures...